CO98 Health Outcomes and Cost-Effectiveness of Atezolizumab in Small Cell Lung Cancer

The aim of this study is to describe the effectiveness of atezolizumab in patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC) and to analyze the cost-effectiveness of treatment in the context of a risk-sharing agreement (RSA) between hospital and pharmaceutical company.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J.F. Marin Pozo, A. Plaza Arbeo, E. Marin Caba, V. Cao Vi ña, R. Contreras Collado, L. Gutierrez Lucena Source Type: research